These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 3766580)

  • 21. Evaluation of an antibiotic restriction policy using a special drug request form.
    Julius HC; Beck K
    Hosp Formul; 1992 Jun; 27(6):638-40, 643. PubMed ID: 10118958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolving concerns of pharmacy and therapeutics committees.
    Weintraub M
    Hosp Formul; 1980 Jan; 15(1):29-31. PubMed ID: 10244955
    [No Abstract]   [Full Text] [Related]  

  • 23. P&T committee: an approach to formulary consideration of antimicrobial agents--introduction.
    Andriole VT; Ryan JL
    Hosp Formul; 1981 Jun; 16(6):619, 623. PubMed ID: 10251442
    [No Abstract]   [Full Text] [Related]  

  • 24. Cost-effective management of DUE (drug utilization evaluation) policy through a pharmacy clerkship.
    Julius HC
    Hosp Formul; 1993 Sep; 28(9):789-91. PubMed ID: 10128394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Compliance with a restricted antimicrobial agent policy in a university hospital.
    Volger BW; Ross MB; Brunetti HR; Baumgartner DD; Therasse DG
    Am J Hosp Pharm; 1988 Jul; 45(7):1540-4. PubMed ID: 3046348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Medical committee enforcement of policy limiting postsurgical antibiotic use.
    Nickman NA; Blissenbach HF; Herrick JD
    Am J Hosp Pharm; 1984 Oct; 41(10):2053-6. PubMed ID: 6496494
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishing a hospital program to improve antimicrobial use, control bacterial resistance and contain healthcare costs: the University of Louisville experience.
    Arnold FW; Patel A; Nakamatsu R; Smith RS; Newman D; Sciortino CV; Peyrani P; Snyder J; Schulz P; Ramirez JA
    J Ky Med Assoc; 2007 Sep; 105(9):431-7. PubMed ID: 17941421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hospital formularies: organizational aspects and supplementary components.
    Rucker TD; Visconti JA
    Am J Hosp Pharm; 1976 Sep; 33(9):912-7. PubMed ID: 984056
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing the hospital pharmacy. Interview by Nancy M. Agresta.
    Lantos RL
    Hosp Formul; 1979 Sep; 14(9):839-43. PubMed ID: 10243910
    [No Abstract]   [Full Text] [Related]  

  • 30. Technician intervention in use of nonformulary antimicrobial agents in the surgical suite.
    Underhill AL; Reno CB; Dougherty FK
    Am J Hosp Pharm; 1989 Feb; 46(2):312-3. PubMed ID: 2712053
    [No Abstract]   [Full Text] [Related]  

  • 31. Working together with medical service representatives.
    Oddis JA
    Resid Staff Physician; 1986 May; 32(5):16. PubMed ID: 10276980
    [No Abstract]   [Full Text] [Related]  

  • 32. Initiation of a clinical pharmacology consult service as a formulary management tool.
    Albertson T; Musallam N; Tharratt S; Romac D; Foulke G; Mowers R; Panecek E
    Hosp Formul; 1993 Aug; 28(8):699-702, 707. PubMed ID: 10127748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How pharmaceutical controls worked in one Ontario hospital.
    McLean WM; Tierney MG
    Can J Hosp Pharm; 1994 Aug; 47(4):176-9. PubMed ID: 10136951
    [No Abstract]   [Full Text] [Related]  

  • 34. Experience with selective reporting of susceptibility to antimicrobial agents.
    Brodowy BA; Guglielmo BJ; York MK; Herfindal ET; Brooks GF
    Am J Hosp Pharm; 1989 Sep; 46(9):1816-8. PubMed ID: 2801717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibiotic order form designed to educate, ease decision making.
    Smith GH
    Hosp Formul; 1990 Apr; 25(4):456-8. PubMed ID: 10104236
    [No Abstract]   [Full Text] [Related]  

  • 36. Linking a policy on nonformulary drugs to the FDA's therapeutic-potential classification system.
    Poirier TI; Vorbach M; Bache T
    Am J Hosp Pharm; 1994 Sep; 51(18):2277-8. PubMed ID: 7801989
    [No Abstract]   [Full Text] [Related]  

  • 37. Achieving rational therapeutics through consensus-based protocols and follow-up.
    Quintiliani R; Gousse GC; Chow MS
    Hosp Formul; 1990 Mar; 25(3):283-4, 289-94. PubMed ID: 10103836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of criteria developed before formulary addition to evaluate misoprostol use.
    Rice KM; LeRoy ML; Ivey MF; Deck C; Krstenansky P
    Am J Hosp Pharm; 1992 Mar; 49(3):629-31. PubMed ID: 1598943
    [No Abstract]   [Full Text] [Related]  

  • 39. P & T Committee interview: strategies to ensure an effective formulary system.
    Riff L; Hutchinson R
    Hosp Formul; 1988 Nov; 23(11):901-4, 907-8. PubMed ID: 10290754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of aminoglycoside-use restrictions on drug cost.
    DeTorres OH; White RE
    Am J Hosp Pharm; 1984 Jun; 41(6):1137-9. PubMed ID: 6430070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.